Skip to Content

Align Technology Inc ALGN Stock Quote

| Rating as of


Market Closed

| Currency in USD

  • Last Close 298.56
  • Sector Healthcare
  • Industry Medical Devices
  • Investment Style Mid Growth
  • Day Range 297.09  –  303.96
  • Year Range 172.05  –  413.20
  • Market Cap 22.8499 Bil
  • Volume / Avg 613,640.0 /  699,620.5
  • Price / Sales 6.19
  • Price / Book 6.28
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis ALGN

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Align Benefits From Improving Trends, Strong Pricing, and Investment in Teen Market

Keonhee Kim Equity Analyst

Business Strategy and Outlook

| Keonhee Kim |

Align Technology is the leading manufacturer of clear aligners. Since it was granted U.S. Food and Drug Administration approval in 1998, the Invisalign brand has dominated the market, providing a diverse set of solutions to patients across the world. The company operates in two segments: clear aligner and systems and services.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics ALGN

Company Profile ALGN

Business Description

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the FDA in 1998, and it has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients’ teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans and iTero scans make up over half of these scans.

410 North Scottsdale Road, Suite 1300
Tempe, AZ, 85281
Industry Medical Devices
Employees 22,910

Related Articles ALGN

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of ALGN’s competitive advantage.

Align Technology Inc


Zimmer Biomet Holdings Inc


Sonova Holding AG


Straumann Holding AG

−$1.72 (0.57%) −$0.95 (0.81%) −$3.50 (1.59%) −$1.00 (0.80%)
Market Cap
22.85 Bil24.42 Bil12.90 Bil19.76 Bil
Medical Devices Medical Devices Medical Devices Medical Instruments & Supplies

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Align Technology Inc Stock

No. ALGN does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

ALGN’s market cap is 22.85 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

ALGN’s stock style is Mid Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

ALGN’s price/sales is 6.19.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

ALGN’s price/forward earnings is 73.36.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

ALGN’s price/book is 6.28.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See ALGN’s valuation ratios compared to the Market Index.

ALGN’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare ALGN’s historical performance against its industry peers and the overall market.